Spirit Airlines Is Shutting Down, Apple Beats, and the Market Celebrates

May opened with new records and Apple delivered a fiscal Q2 beat that the market had been waiting for all week. 

Iran reportedly sent a peace proposal through Pakistani mediators, pulling oil lower, before Trump said he is not satisfied with the terms. We break down every name that moved on a day that had something for everyone.

A potential executive order tied to financial policy is drawing attention from market watchers.

Moves of this scale can ripple across currencies, savings, and hard assets.

With renewed focus on gold reserves and valuation, some believe a major shift could be unfolding.

Understanding the implications early may be key.

Learn how this could impact your strategy

Four senior insiders at one oil stock sold a combined $5.6 million worth of shares across two straight sessions, even as a bank director lined up another $3.4 million sale with the stock near fresh highs.

Insider readers will see where leadership is cashing in while the market keeps celebrating fresh all-time highs.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Apple beat fiscal Q2 earnings after Thursday's close and gained, giving the market its fresh start to May as Iran reportedly sent a new peace proposal through Pakistani mediators that pulled oil lower before Trump said he is not satisfied with the terms.

The software sector posted its best single earnings day of the season, with Atlassian beating on revenue and raising guidance, Five9 raising its full-year outlook, and Bandwidth reporting record quarterly revenue.

Trump threatened 25% tariffs on EU cars and trucks, sending European auto names lower, while Spirit Airlines fell sharply after the WSJ reported it is preparing to shut down following the collapse of a government rescue deal.

Atlassian Corporation (NASDAQ: TEAM) has spent most of 2026 getting punished for a problem it does not actually have.

The entire software industry got swept up in fears that AI tools from companies like OpenAI and Anthropic would replace enterprise platforms.

Atlassian took one of the hardest hits. The company responded by cutting 1,600 jobs, redirecting the savings into AI development, and embedding artificial intelligence directly into its products.

That bet is now paying off in ways the doubters did not expect, as overall revenue grew 32% from a year ago.

Restructuring With Purpose

Cutting 10% of the workforce is painful. Doing it to fund a strategic pivot into AI and enterprise sales is deliberate.

Atlassian did not shrink out of weakness. It reorganized to compete in a landscape that changed overnight.

That distinction matters. Your perception of layoffs shifts when the company that made them delivers accelerating growth months later.

The Bigger Question Remains

Atlassian answered the immediate crisis. The longer-term question about AI's impact on enterprise software is still open. But right now, one company has shown that adaptation beats fear.

You watch the rest of the software industry scramble for answers, and Atlassian already found one. Whether others follow fast enough is the story that defines this entire sector for the next several years.

Rhythm Pharmaceuticals (NASDAQ: RYTM) just received European Commission approval for Imcivree, a treatment for acquired hypothalamic obesity in adults and children as young as four.

Imcivree is the first and only approved treatment for this condition in Europe. It received U.S. approval in March. Rhythm now owns this disease category on two continents.

First Mover in a Category of One

There are no competitors here—no alternative therapies.

When a patient receives this diagnosis in Europe, there is exactly one approved treatment, and Rhythm makes it. That kind of market exclusivity is extraordinarily rare in pharma.

You hear about drug approvals constantly. Most enter crowded markets with dozens of alternatives. This one enters a market where it is the only option.

Europe Launches in 2027

Rhythm plans country-by-country commercial launches across Europe starting next year. Each country requires its own access application and pricing negotiation.

The rollout takes time, but the runway is clear and uncontested.

Rhythm is not a pharma giant. Securing regulatory approval on two continents for a first-in-class treatment transforms the company's trajectory entirely.

It goes from clinical-stage biotech to global commercial operation in a matter of months.

You find a company that owns the only approved treatment for a condition affecting patients worldwide, with no alternatives available, and the word "niche" no longer applies.

That is not a niche. That is a monopoly by necessity.

Confirmed by satellites 300 miles above the Earth's surface...

Elon Musk is rolling out a breakthrough technology that could replace our need for foreign oil and ignite a $10 trillion boom for a small group of stocks.

Click here to learn how you can invest in this before it becomes mainstream.

Exxon Mobil Corporation (NYSE: XOM) just reported its weakest profit in five years.

Not because the business failed. Because the Iran war disrupted operations across the Middle East so severely that production dropped sharply from the prior quarter.

About 20% of Exxon's total production sits in the Middle East. That exposure is now the company's most visible risk.

Guyana Saved the Quarter

While the Middle East dragged down results, Guyana set a new production record. The Permian Basin kept growing, too.

These two regions carried the quarter and proved exactly why Exxon has been investing so heavily in both.

You look at the contrast, and the lesson is blunt. The assets Exxon built outside the Middle East are the ones keeping the company afloat during the worst regional disruption in years.

Strategy Gets Tested in Moments Like This

Exxon has spent years building a portfolio designed to perform through volatility. Guyana, the Permian, low-cost production, disciplined spending. This quarter is the stress test.

You judge a company's strategy not when everything goes right but when the world falls apart around it. Exxon's Middle East exposure took a serious hit.

Its Western Hemisphere assets held firm. That split defines where this company is heading and what it is quietly leaving behind.

Cue Biopharma [CUE] $30.42 (+106.38%)

Cue received a $7.5 million milestone payment from its Ascendant Digital Therapeutics partnership on May 1 and announced a $30 million private placement closing May 4.

With 278% short interest as a percentage of float, any positive catalyst creates violent squeeze dynamics. The autoimmune and oncology pipeline is advancing with a Phase 2 program potentially reaching an inflection in the second half of 2026.

Atlassian [TEAM] $88.88 (+29.58%)

Atlassian reported Q3 revenue of $1.79 billion, up 32% year-over-year, with cloud growing 29% and data center growing 44%, and raised full-year revenue growth guidance to approximately 24%.

The Service Collection crossed $1 billion in annual recurring revenue with over 30% growth, and free cash flow hit $561 million. The quarter directly challenged the narrative that AI is disrupting rather than accelerating enterprise software demand.

Five9 [FIVN] $22.24 (+29.30%)

Five9 reported Q1 EPS beating the consensus by 23% on revenue up 9% year-over-year, and raised its full-year revenue guidance. Management announced an accelerated $90 million share repurchase and said AI revenue acceleration arrived earlier than anticipated.

Backlog converting faster than planned is the primary catalyst, confirming Five9's positioning as a cloud contact center platform for AI-driven enterprise deployments.

Summit Therapeutics [SMMT] $16.12 (-24.91%)

Summit reported Q1 non-GAAP net loss of $116.6 million, more than doubling year-over-year, as R&D expenses exceeded $108 million on expanding Phase 3 trials.

Ivonescimab's interim analysis was described as "uneventful," removing hope of an early efficacy read and leaving the $12.85 billion company with no near-term catalyst to justify current valuation against accelerating cash burn.

LendingTree [TREE] $38.81 (-21.74%)

LendingTree delivered record Q1 revenue and adjusted EBITDA up 71% year-over-year, but fell on cautious forward guidance and sell-the-news dynamics after a strong April run.

Home and consumer lending face persistent headwinds from elevated oil-driven rates, and the $555 million Strong Buy-rated company guided conservatively enough to disappoint investors positioned for continuation of the record-beat momentum.

Roblox [RBLX] $45.13 (-18.33%)

Roblox reported Q1 daily active users of 132 million, missing the 143.8 million estimate, and cut full-year bookings guidance to $7.33-7.6 billion from prior guidance of $8.28-8.55 billion.

Child safety age-gating restricted user intercommunication and suppressed engagement. The guidance cut of over one billion dollars at the midpoint is the entire story, as revenue trends otherwise remained strong.

Elon has spent decades assembling the ultimate puzzle…

What's Elon's master plan? Because it's not just to make him richer… he already has more money than you could spend in a thousand lifetimes.

There's something much, much bigger happening.

Click here to see the document that shows exactly how all the pieces fit together.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.